Legakis NJ - Search Results

1

Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be.

Tzouvelekis LS, Gazouli M, Prinarakis EE, Tzelepi E, Legakis NJ. Tzouvelekis LS, et al. Among authors: legakis nj. Antimicrob Agents Chemother. 1997 Feb;41(2):475-7. doi: 10.1128/AAC.41.2.475. Antimicrob Agents Chemother. 1997. PMID: 9021212 Free PMC article.

2

Prevalence of the type I and type II DHFR genes in trimethoprim-resistant urinary isolates of Escherichia coli from Greece.

Tsakris A, Johnson AP, Legakis NJ, Tzouvelekis LS. Tsakris A, et al. Among authors: legakis nj. J Antimicrob Chemother. 1993 May;31(5):665-71. doi: 10.1093/jac/31.5.665. J Antimicrob Chemother. 1993. PMID: 8392996

3

In vitro activity of cefpirome against selected clinical enterobacterial isolates with beta-lactamase-mediated resistance.

Tzouvelekis LS, Tzelepi E, Mentis AF, Legakis NJ. Tzouvelekis LS, et al. Among authors: legakis nj. Infection. 1995 Nov-Dec;23(6):384-7. doi: 10.1007/BF01713572. Infection. 1995. PMID: 8655212

4

In vitro activity of cefetamet against enterobacteria expressing an SHV-5-type beta-lactamase.

Tzouvelekis LS, Prinarakis EE, Gazouli M, Miriagou V, Tzelepi E, Legakis NJ. Tzouvelekis LS, et al. Among authors: legakis nj. Chemotherapy. 1996 Sep-Oct;42(5):324-8. doi: 10.1159/000239462. Chemotherapy. 1996. PMID: 8874970

5

Substitution of Arg-244 by Cys or Ser in SHV-1 and SHV-5 beta-lactamases confers resistance to mechanism-based inhibitors and reduces catalytic efficiency of the enzymes.

Giakkoupi P, Tzelepi E, Legakis NJ, Tzouvelekis LS. Giakkoupi P, et al. Among authors: legakis nj. FEMS Microbiol Lett. 1998 Mar 1;160(1):49-54. doi: 10.1111/j.1574-6968.1998.tb12889.x. FEMS Microbiol Lett. 1998. PMID: 9495011

6

Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position 69.

Giakkoupi P, Miriagou V, Gazouli M, Tzelepi E, Legakis NJ, Tzouvelekis LS. Giakkoupi P, et al. Among authors: legakis nj. Antimicrob Agents Chemother. 1998 May;42(5):1281-3. doi: 10.1128/AAC.42.5.1281. Antimicrob Agents Chemother. 1998. PMID: 9593168 Free PMC article.

7

In vitro activity of loracarbef against TEM extended-spectrum beta-lactamase-producing Escherichia coli strains and its interaction with the enzymes.

Prinarakis EE, Tzouvelekis LS, Legakis NJ. Prinarakis EE, et al. Among authors: legakis nj. Chemotherapy. 1998 Jul-Aug;44(4):260-4. doi: 10.1159/000007122. Chemotherapy. 1998. PMID: 9681202

8

Two novel plasmid-mediated cefotaxime-hydrolyzing beta-lactamases (CTX-M-5 and CTX-M-6) from Salmonella typhimurium.

Gazouli M, Tzelepi E, Markogiannakis A, Legakis NJ, Tzouvelekis LS. Gazouli M, et al. Among authors: legakis nj. FEMS Microbiol Lett. 1998 Aug 15;165(2):289-93. doi: 10.1111/j.1574-6968.1998.tb13159.x. FEMS Microbiol Lett. 1998. PMID: 9742701

9

Effect of substitution of Asn for Arg-276 in the cefotaxime-hydrolyzing class A beta-lactamase CTX-M-4.

Gazouli M, Legakis NJ, Tzouvelekis LS. Gazouli M, et al. Among authors: legakis nj. FEMS Microbiol Lett. 1998 Dec 15;169(2):289-93. doi: 10.1111/j.1574-6968.1998.tb13331.x. FEMS Microbiol Lett. 1998. PMID: 9868772

10

Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.

Giakkoupi P, Tzelepi E, Legakis NJ, Tzouvelekis LS. Giakkoupi P, et al. Among authors: legakis nj. J Antimicrob Chemother. 1999 Jan;43(1):23-9. doi: 10.1093/jac/43.1.23. J Antimicrob Chemother. 1999. PMID: 10381097

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

201 results

Search Page

Filters